Navigation Links
Pharsight Launches PK Accelerator(TM)
Date:6/24/2008

PK Accelerator Bundled Solution Accelerates Pharmacokinetic Analysis and

Reporting

MOUNTAIN VIEW, Calif., June 24 /PRNewswire-FirstCall/ -- Pharsight Corporation (Nasdaq: PHST), a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, today announced that it will be launching PK Accelerator (PKA(TM)), a system of bundled software coupled with a rapid deployment service provided at a fixed price and fixed scope. Adopting PK Accelerator will allow small to mid-sized organizations to deploy Pharsight's "best practices" solution for end-to-end pharmacokinetic analysis and validatable CFR 21 part 11 reporting in as little as 90 days.

Small to mid-sized research oriented pharmaceutical and biotech companies deploying PK Accelerator will be able to take advantage of the operational efficiencies Pharsight's enterprise and desktop software packages were designed to deliver. The software components of the PKA bundle will consist of the Pharsight(R) Knowledgebase Server(TM) (PKS), WinNonlin(R) Autopilot(TM), PKS Reporter(TM), the PKS and WinNonlin Validation Suites(TM), upgrades to WinNonlin Enterprise, and a choice of two of the following database connectors: Watson(TM), Excel(TM), or CDISC. All of these components have been designed for seamless interoperability and will be implemented as a complete system with minimal configuration. PK Accelerator will bring state-of-the-art clinical pharmacology archiving, analysis, and reporting capabilities within reach of smaller firms by standardizing the system's training and deployment procedures and leveraging Pharsight's best practices recommendations for system configuration and implementation.
'/>"/>

SOURCE Pharsight Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Pharsight to Present on IVIVC at Bioequivalence & Bioavailability Strategies Conference
2. Pharsight to Present on Literature-Based Disease Modeling Approaches at AAPS National Biotechnology Conference
3. Pharsight Hosts European PKS User Meeting
4. Pharsight Achieves $7.6 Million In Quarterly Revenue
5. Pharsight Signs Two New DMX(R) License Customers
6. Pharsight to Present at B. Riley & Co. 9th Annual Las Vegas Investor Conference
7. Pharsight Makes Strong Contribution to Inaugural American Conference on Pharmacometrics
8. Pharsights Reporting and Analysis Services Business Unit to Leverage New Validated Data Management System
9. Pharsight Welcomes Newest Japanese PKS, AutoPilot Customer
10. Pharsight to Present at Jesup and Lamont 2008 Emerging Growth Stock Conference
11. Pharsight Achieves $7.4 Million in Quarterly Revenue
Post Your Comments:
*Name:
*Comment:
*Email: